Lepu Biopharma Co., Ltd. (2157.HK)

3,540 -0,140 (-3,80%) Alla chiusura: 04:08PM HKT

Lepu Biopharma Co., Ltd.

No. 651, Lianheng Road
Minhang District
Shanghai 201612
China
86 21 6768 0899
https://www.lepubiopharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 429

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Zhongjie Pu	Executive Chairman	N/D	N/D	1963
Dr. Ziye Sui M.D., Ph.D.	CEO & Director	2,95M	N/D	1981
Ms. Yunyi Li	CFO & Board Secretary	N/D	N/D	1980
Dr. Minmin Qin Ph.D.	Chief Technology Officer	N/D	N/D	1958
Ms. Lixuan Zhao	Supervisor & Investor Relations Director	N/D	N/D	1992
Ms. Siu Kuen Lai FCIS, FCS	Joint Company Secretary	N/D	N/D	1976

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China.

Governance aziendale

L'ISS Governance QualityScore di Lepu Biopharma Co., Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.